Lovastatin Tablet
Product Images NDC 70518-2425

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 70518-2425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Lovastatin 40 mg tablet label from RemedyRepack Inc. The label indicates a quantity of 90 tablets in a round white form. It includes storage instructions to keep out of reach of children and store at 20-25°C with excursions permitted to 15-30°C. The manufacturer is Carlsbad Tech, Inc., Carlsbad, CA.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin, showing its molecular arrangement with multiple ring structures and functional groups including hydroxyl and ester components.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing the number of subjects, dosing of coadministered drug or grapefruit juice, dosing of lovastatin, and AUC ratio comparing lovastatin exposure with and without the coadministered drug for various drugs including Gemfibrozil, Itraconazole, Grapefruit Juice at high and low doses, Cyclosporine, and Diltiazem.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph depicting the proportion of participants without acute major coronary events over six years of follow-up, comparing Lovastatin and placebo groups. The graph shows a 37% risk reduction with Lovastatin treatment versus placebo (p<0.001). The y-axis represents the proportion of participants without events, ranging from 0.90 to 1.0, and the x-axis shows years of follow-up from 0 to 6.*

FDA Label Image

Table Vii (Lov00 0005 04)

Data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing interacting agents such as CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, and others, along with prescribing recommendations including contraindications, dosage limits, and avoidance of grapefruit juice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.